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ABSTRACT Mutations in crrAB genes encoding a two-component regulator involved in
modiﬁcations of lipopolysaccharide were searched for among a collection of colistin-
resistant Klebsiella pneumoniae isolates. Four isolates, respectively, producing carbapen-
emases NDM-1, OXA-181, or KPC-2 showed mutated CrrB proteins compared with those
in wild-type strains. Complementation assays with a wild-type CrrB protein restored the
susceptibility to colistin in all cases, conﬁrming the involvement of the identiﬁed substi-
tutions in the resistance phenotype.
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The emergence and spread of carbapenemase-producing Klebsiella pneumoniaeisolates worldwide has forced clinicians to reintroduce colistin as last-resort therapy
(1). Besides the plasmid-mediated mcr-1 and mcr-2 genes in K. pneumoniae (2, 3), the
chromosomally encoded alterations of the mgrB gene and the PmrAB and PhoPQ
two-component systems are currently the most commonly reported mechanisms of
acquisition of polymyxin resistance in this enterobacterial species (4). Recently, muta-
tions in the crrB gene, belonging to a third two-component system (named CrrAB for
colistin resistance regulation) and involved in lipopolysaccharide (LPS) modiﬁcations,
were associated with colistin resistance (5, 6). Mutations in the crrB gene are responsible
for the increase in crrC gene transcription, which in turn regulates the expression of the
pmrC gene and the pmrHFIJKLM operon, through the PmrAB two-component system
(6). Expression of these genes leads to the addition of cationic groups on the LPS and
consequently to colistin resistance.
In previous studies, the colistin resistance mechanisms of a collection of 185 K.
pneumoniae isolates recovered from human samples worldwide (Europe, Turkey, Co-
lombia, South Africa) were analyzed. Chromosomally encoded modiﬁcations of LPS
through alterations (mutation, truncation) of the mgrB gene (7–9), the pmrAB genes
(10), or the phoPQ genes (11) were identiﬁed in 152 isolates. However, 33 isolates did
not present any substitutions in these genes, and they were negative for the plasmid-
mediated resistance genes mcr-1 and mcr-2.
We analyzed the genes encoding the CrrAB system in these 33 isolates. Ampliﬁcation of
the crrA and crrB genes was performed using primers crrAB-extF (5=-GTGAGGCCATCAAAT
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TCTCG-3=) and crrAB-extR (5=-AAGTCCCAAAAGAGGCAAAC-3=) located on each extremity
of this operon. No ampliﬁcation was obtained with the primers for 19 of the 33 isolates.
We obtained the same result by using internal primers annealing into the crrB gene,
namely, crrB-intF (5=-GTGACTATCTTACGTGGGAG-3=) and crrB-intR (5=-CACTCAGCATCA
AGGAGTAC-3=). This absence of ampliﬁcation suggested an absence of the crrAB
operon in these strains, which is in accordance with the variability of the lateral
acquisition of the crrAB operon in K. pneumoniae (5). Ampliﬁcation of the crrAB gene was
obtained for the 14 remaining isolates. Subsequent sequencing identiﬁed mutations lead-
ing to amino acid changes (F84S, N141Y, P151L, and G183V) in the CrrB protein in 4 of the
14 colistin-resistant K. pneumoniae isolates (Table 1).
Three of the CrrB amino acid substitutions were located in the histidine kinase
A (HisKA) phosphoacceptor domain (amino acids 136 to 200) (Table 1). Previously,
four mutations in this HisKA domain were found to be involved in colistin resistance
(6) (Table 1). Among them, two were at the same position as the mutations
observed in our strains (amino acids 141 and 151), but the amino acid changes were
different. The fourth strain presented a mutation in the HAMP domain of CrrB,
whereas a single mutation in this domain has been shown (5). All of the substitu-
tions in the CrrB protein, known to be responsible for colistin resistance, are shown
in Table 1.
Determination of the colistin MICs by use of the reference broth microdilution
method showed a high level of colistin resistance (MIC of colistin, 128 g/ml for all
four isolates with mutated crrB genes) (Table 1). The high MICs of colistin in the K.
pneumoniae strains are in accordance with results reported by Cheng et al. (6) (Table 1).
Furthermore, Wright et al. (5) reported lower MICs of colistin (16 g/ml) for two isolates
exhibiting CrrB mutations. However, MICs were determined by use of the Etest strip
technique, which is known to underestimate colistin MIC values (12).
We performed complementation assays to conﬁrm the involvement of the mutated
crrB gene in the colistin resistance phenotype. A recombinant plasmid (pTRIC) was built
by cloning a triclosan resistance gene (mFabI) (13) into the low-copy-number plasmid
pBR322. The wild-type crrB gene from the colistin-susceptible K. pneumoniae strain
Af44a (MIC of colistin, 0.25 g/ml) was ampliﬁed by PCR and cloned into this plasmid.
The recombinant crrB-pTRIC plasmid and the pTRIC plasmid were separately trans-
formed by electroporation into the four resistant strains presenting the mutations in
the crrB gene. Transformants were selected by overnight incubation at 37°C on Mueller-
Hinton agar supplemented with triclosan (1 M), and the recombinant clones were
checked by PCR and sequencing. MICs of colistin for the transformants revealed that
production of a wild-type CrrB protein (crrB-pTRIC plasmid) restored the susceptibility
to colistin in all isolates (MIC, 0.5 g/ml) (Table 1), conﬁrming that the different
substitutions in CrrB were, respectively, responsible for the resistant phenotypes. As
expected, transformation with the pTRIC plasmid used as a negative control did not
restore any susceptibility to colistin.
All isolates presenting a CrrB amino acid change produced a carbapenemase
(NDM-1, OXA-181, or KPC-2) (Table 1). They were recovered from patients who had
been treated with colistin in Colombia, France, Greece, and South Africa. For the
patient harboring the colistin-resistant isolate Af44b, one colistin-susceptible iso-
late (Af44a) was recovered before the colistin treatment, and pulsed-ﬁeld gel
electrophoresis analysis conﬁrmed the clonal relationship of the two isolates (data
not shown). Sequencing of the crrB gene of the Af44a isogenic susceptible strain
identiﬁed a wild-type CrrB protein, reinforcing the hypothesis that the in vivo
emergence of colistin resistance under colistin pressure might be related to CrrB
mutations in some instances.
In conclusion, four novel mutations in the CrrB protein were identiﬁed at the sources
of acquisition of high-level colistin resistance among carbapenemase-producing K.
pneumoniae.
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